Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and non-vitamin K antagonist oral anticoagulant therapy
CONCLUSIONS: The combination therapy group had higher incidences of any bleeding events compared to the monotherapy in patients with appropriate dosing. However, there was no difference in stroke/SE, and MACE. The bleeding risk in AF patients taking the combination of NOACs and APT should be carefully evaluated.PMID:35092194 | DOI:10.31083/j.rcm2301002
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Authors: Dong Geum Shin Sunhwa Kim Yoo Ri Kim Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Ischemic Stroke | Stroke | Study | Vitamin K | Vitamins